Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk continues to dominate the global diabetes and obesity care markets with its portfolio of blockbuster GLP-1 therapies. Regeneron Pharmaceuticals maintains a strong foothold in ophthalmology and immunology while expanding its pipeline through strategic collaborations.

The Motley Fool • Sep 15, 2026

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum

Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.

MarketBeat • Sep 15, 2026

REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

PRNewsWire • Sep 14, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.

Business Wire • Sep 14, 2026

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and.

Business Wire • Sep 14, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026

GlobeNewsWire • Sep 13, 2026

REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until tomorrow, Monday, September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit.

PRNewsWire • Sep 13, 2026

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth

Regeneron Pharmaceuticals NASDAQ: REGN executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance.

MarketBeat • Sep 12, 2026

REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

SAN FRANCISCO, Sept. 12, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

GlobeNewsWire • Sep 12, 2026